NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vibrant Therapeutics

Vibrant Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vibrantx.com/

Last Round

Series B

Jan 12, 2026

Total Funding Raised

$64.35M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vibrant Therapeutics is a biotechnology company that develops intelligent, logic-gated therapeutics designed to selectively activate in the desired disease microenvironment.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

medical deviceingestible capsulechronic constipationdigital healthdrug-free treatmentmechanical stimulationgastroenterologysmart pillnon-pharmacological therapybioelectronic medicineprescribed medical devicegastrointestinal disordermedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vibrant Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Vibrant Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vibrant Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 12, 2026
Series A ExtensionAug 25, 2025
Series AAug 25, 2025
Series AJul 19, 2023

Vibrant Therapeutics Investors

Notable investors and investment history

Vibrant Therapeutics investors
InvestorRounds
First Principle Venture LimitedSeries B
Advantage CapitalSeries A
Northern Light Venture CapitalSeries B
Bayland CapitalSeries B
HongShanSeries A, Series B
Trinity Innovation FundSeries A
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors grew 292% MoM, from 275 to 1.1K.

  • Jan 15, 2026

    Han Lee appointed co-chief executive officer alongside founder Larry Wang.

Vibrant Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vibrant Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vibrant Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range10
Year Founded2019
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.